Pfizer Inc. (PFE) Stock Forecast
PFE analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.54 / 5 from 28 analysts
- Price target
- $29.26 average of analyst targets
- Upside to target
- −1.1% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.72
- 52-week range
- $23.67 – $29.58
PFE analyst ratings
28 analystsNumber of analysts at each rating.
PFE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PFE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.73 | $0.56 | $0.84 | $0.87 | −15.8% | 19 |
| Current fiscal year (2026) | $2.96 | $2.88 | $3.07 | $3.22 | −8.1% | 25 |
| Next fiscal year (2027) | $2.89 | $2.52 | $3.15 | $2.96 | −2.5% | 23 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PFE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $15.92B | $14.69B | $16.85B | −4.4% | 17 |
| Current fiscal year (2026) | $62.22B | $61.16B | $63.28B | −0.6% | 25 |
| Next fiscal year (2027) | $59.86B | $58.39B | $62.49B | −3.8% | 23 |
PFE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PFE revenue: reported and forecast
PFE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.82 | $0.76 | $0.76 | $0.74 | $0.73 | −10.8% | 1 up · 6 down |
| Current fiscal year (2026) | $2.95 | $2.98 | $2.98 | $2.97 | $2.96 | +0.4% | 1 up · 4 down |
| Next fiscal year (2027) | $2.83 | $2.90 | $2.90 | $2.90 | $2.89 | +2.0% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PFE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PFE beat in 12 of 12.
What analysts expect from PFE
28 analysts cover Pfizer; their consensus rating is buy (3.54 on a 1–5 scale, where 5 is a strong buy). The average price target is $29.26, 1.1% below the latest close of $29.58. Analysts expect earnings of $2.96 per share for 2026, −8.1% from a year earlier. For 2027 the average estimate is $2.89 per share on revenue of $59.9 billion. Pfizer beat the EPS estimate in 12 of the last 12 quarters.
Related: PFE income statement, PFE key metrics, PFE chart. See the PFE stock overview for the latest quote and news.
PFE forecast FAQ
What is Pfizer's price target?
The average analyst price target for Pfizer is $29.26, 1.1% below the latest close of $29.58.
Is Pfizer a buy, hold or sell?
Of 28 analysts covering Pfizer, 8 rate it a strong buy, 2 a buy, 16 a hold, 1 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pfizer's EPS forecast?
Analysts forecast $2.96 per share for 2026 (range $2.88 to $3.07); for 2027 the estimate is $2.89.
What is Pfizer's revenue forecast?
The average revenue estimate for 2026 is $62.2 billion, growth of −0.6%; for 2027 it is $59.9 billion.
When does Pfizer report earnings?
Pfizer is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.72.
Does Pfizer usually beat earnings estimates?
Pfizer reported EPS at or above the analyst estimate in 12 of the last 12 quarters.